In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will acquire treatment until eventually condition progression or perhaps the contributors are not able to tolerate the study drugs. Celastrol was identified for a Myb inhibitor that suppressed C/EBPβ activity https://emilianogwkev.wizzardsblog.com/31905386/details-fiction-and-abbv-744-in-acute-myeloid-leukemia-aml